Health
Astra, Daiichi Drug Extends Lives of Some Lung Cancer Patients
This article is for subscribers only.
AstraZeneca Plc and partner Daiichi Sankyo Co.’s experimental drug Dato-DXd helped extend the lives of some lung cancer patients in a late-stage study.
The drug already showed it could stave off cancer’s worsening last year. Now, researchers have looked at the data to determine whether it actually helped prolong patients’ lives — a key gauge called overall survival.